{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:46:05Z","timestamp":1773780365962,"version":"3.50.1"},"reference-count":127,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Cardiovasc. Med."],"DOI":"10.3389\/fcvm.2015.00003","type":"journal-article","created":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T15:46:21Z","timestamp":1423064781000},"source":"Crossref","is-referenced-by-count":8,"title":["Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!"],"prefix":"10.3389","volume":"2","author":[{"given":"Giuseppe","family":"Maiolino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Azzolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Paolo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2015,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jama.290.2.199","article-title":"Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000","volume":"290","author":"Hajjar","year":"2003","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.HYP.36.4.594","article-title":"Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community","volume":"36","author":"Lloyd-Jones","year":"2000","journal-title":"Hypertension"},{"key":"B3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/HYPERTENSIONAHA.114.03718","article-title":"Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel","volume":"64","author":"Weitzman","year":"2014","journal-title":"Hypertension"},{"key":"B4","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.03.115","article-title":"Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension","volume":"18","author":"Pierdomenico","year":"2005","journal-title":"Am J Hypertens"},{"key":"B6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"key":"B7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"key":"B8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis","volume":"31","author":"Jung","year":"2013","journal-title":"J Hypertens"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/hr.2010.183","article-title":"Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy","volume":"34","author":"Ceral","year":"2011","journal-title":"Hypertens Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1097\/HJH.0b013e32834c465d","article-title":"Drug-related hypertension and resistance to antihypertensive treatment: a call for action","volume":"29","author":"Rossi","year":"2011","journal-title":"J Hypertens"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1097\/00004872-200111000-00018","article-title":"High prevalence of cardiac and extracardiac target organ damage in refractory hypertension","volume":"19","author":"Cuspidi","year":"2001","journal-title":"J Hypertens"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American heart Association professional education committee of the council for high blood pressure research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"d4891","DOI":"10.1136\/bmj.d4891","article-title":"Management of hypertension: summary of NICE guidance","volume":"343","author":"Krause","year":"2011","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National heart, lung, and blood institute, national high blood pressure education program coordinating committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ajh.2011.210","article-title":"Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review)","volume":"25","author":"Graudal","year":"2012","journal-title":"Am J Hypertens"},{"key":"B18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/archinternmed.2009.470","article-title":"Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study","volume":"170","author":"Blumenthal","year":"2010","journal-title":"Arch Intern Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"key":"B20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1161\/01.HYP.0000184225.05629.51","article-title":"Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors","volume":"46","author":"Cornelissen","year":"2005","journal-title":"Hypertension"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/archinte.158.11.1197","article-title":"Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure","volume":"158","author":"Cushman","year":"1998","journal-title":"Arch Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/01.HYP.37.2.187","article-title":"Association between smoking and blood pressure: evidence from the health survey for England","volume":"37","author":"Primatesta","year":"2001","journal-title":"Hypertension"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/eurheartj\/eht028","article-title":"Treatment-resistant hypertension: another Cinderella story","volume":"34","author":"Messerli","year":"2013","journal-title":"Eur Heart J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1097\/HJH.0b013e32834a8a42","article-title":"Baseline predictors of resistant hypertension in the Anglo-Scandinavian cardiac outcome trial (ASCOT): a risk score to identify those at high-risk","volume":"29","author":"Gupta","year":"2011","journal-title":"J Hypertens"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/CIRCULATIONAHA.112.097345","article-title":"Resistant hypertension: incidence, prevalence, and prognosis","volume":"125","author":"Pimenta","year":"2012","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003-2008","volume":"57","author":"Persell","year":"2011","journal-title":"Hypertension"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.amjhyper.2005.06.013","article-title":"True resistant hypertension: is it possible to be recognized in the office?","volume":"18","author":"Muxfeldt","year":"2005","journal-title":"Am J Hypertens"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1097\/HJH.0b013e328353634e","article-title":"Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs","volume":"30","author":"de la Sierra","year":"2012","journal-title":"J Hypertens"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/jhh.2009.35","article-title":"Urinary albumin excretion is associated with true resistant hypertension","volume":"24","author":"Oliveras","year":"2010","journal-title":"J Hum Hypertens"},{"key":"B36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/HYPERTENSIONAHA.110.165563","article-title":"Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives","volume":"57","author":"Oliveras","year":"2011","journal-title":"Hypertension"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/archinte.168.21.2340","article-title":"Prognostic influence of office and ambulatory blood pressures in resistant hypertension","volume":"168","author":"Salles","year":"2008","journal-title":"Arch Intern Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/eurheartj\/ehs368","article-title":"Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis","volume":"34","author":"Kumbhani","year":"2013","journal-title":"Eur Heart J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/01.HYP.0000127424.59774.84","article-title":"Blood pressure control and physician management of hypertension in hospital hypertension units in Spain","volume":"43","author":"Banegas","year":"2004","journal-title":"Hypertension"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e24569","DOI":"10.1371\/journal.pone.0024569","article-title":"Physician perception of blood pressure control and treatment behavior in high-risk hypertensive patients: a cross-sectional study","volume":"6","author":"Banegas","year":"2011","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e7473","DOI":"10.1136\/bmj.e7473","article-title":"Resistant hypertension","volume":"345","author":"Myat","year":"2012","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2337\/dc07-0031","article-title":"Primary aldosteronism in diabetic subjects with resistant hypertension","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/HJH.0b013e328360ddf6","article-title":"Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China","volume":"31","author":"Sang","year":"2013","journal-title":"J Hypertens"},{"key":"B45","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.179788","article-title":"Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension","volume":"58","author":"Pedrosa","year":"2011","journal-title":"Hypertension"},{"key":"B46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.amjcard.2013.10.046","article-title":"Prevalence of and risk factors of renal artery stenosis in patients with resistant hypertension","volume":"113","author":"Benjamin","year":"2014","journal-title":"Am J Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1001\/jama.275.20.1590","article-title":"Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials","volume":"275","author":"Midgley","year":"1996","journal-title":"JAMA"},{"key":"B48","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrendo.2011.76","article-title":"A comprehensive review of the clinical aspects of primary aldosteronism","volume":"7","author":"Rossi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"},{"key":"B52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"B54","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the antihypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1210\/endo-118-2-819","article-title":"Intracerebroventricular infusion of aldosterone induces hypertension in rats","volume":"118","author":"Gomez-Sanchez","year":"1986","journal-title":"Endocrinology"},{"key":"B57","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","article-title":"Aldosterone induces contraction of the resistance arteries in man","volume":"166","author":"Romagni","year":"2003","journal-title":"Atherosclerosis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1161\/HYPERTENSIONAHA.113.02989","article-title":"Racial differences in sensitivity of blood pressure to aldosterone","volume":"63","author":"Tu","year":"2014","journal-title":"Hypertension"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1161\/HYPERTENSIONAHA.114.03127","article-title":"Sensitivity to aldosterone: plasma levels are not the full story","volume":"63","author":"Funder","year":"2014","journal-title":"Hypertension"},{"key":"B62","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","article-title":"Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension","volume":"25","author":"Shibata","year":"2012","journal-title":"Am J Hypertens"},{"key":"B63","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/35024095","article-title":"AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration","volume":"407","author":"AbdAlla","year":"2000","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cvr\/cvn064","article-title":"Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization","volume":"79","author":"Yamada","year":"2008","journal-title":"Cardiovasc Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/01.HYP.33.4.981","article-title":"Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis","volume":"33","author":"Robert","year":"1999","journal-title":"Hypertension"},{"key":"B66","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.amjhyper.2005.01.002","article-title":"Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension","volume":"18","author":"Nishizaka","year":"2005","journal-title":"Am J Hypertens"},{"key":"B67","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","article-title":"Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial","volume":"54","author":"Pimenta","year":"2009","journal-title":"Hypertension"},{"key":"B68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/00000441-198912000-00001","article-title":"Plasma volume in resistant hypertension: guide to pathophysiology and therapy","volume":"298","author":"Graves","year":"1989","journal-title":"Am J Med Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","article-title":"Resistant hypertension: comparing hemodynamic management to specialist care","volume":"39","author":"Taler","year":"2002","journal-title":"Hypertension"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e52229","DOI":"10.1371\/journal.pone.0052229","article-title":"Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients","volume":"7","author":"Labeit","year":"2012","journal-title":"PLoS One"},{"key":"B72","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/01.HYP.0000242642.42177.49","article-title":"Mechanisms of sympathetic activation in obesity-related hypertension","volume":"48","author":"Esler","year":"2006","journal-title":"Hypertension"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1210\/jc.2008-0251","article-title":"Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients","volume":"93","author":"Rossi","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2869.2010.00839.x","article-title":"Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension","volume":"19","author":"Lloberes","year":"2010","journal-title":"J Sleep Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1378\/chest.07-1170","article-title":"Obstructive sleep apnea and resistant hypertension: a case-control study","volume":"132","author":"Goncalves","year":"2007","journal-title":"Chest"},{"key":"B76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5664\/jcsm.27878","article-title":"Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension","volume":"6","author":"Gonzaga","year":"2010","journal-title":"J Clin Sleep Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1097\/HJH.0b013e32833b9c63","article-title":"Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial","volume":"28","author":"Lozano","year":"2010","journal-title":"J Hypertens"},{"key":"B78","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/HJH.0b013e328350e53b","article-title":"Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European society of hypertension, by the European respiratory society and by the members of European Cost (cooperation in scientific and technological RESEARCH) ACTION B26 on obstructive sleep apnea","volume":"30","author":"Parati","year":"2012","journal-title":"J Hypertens"},{"key":"B79","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J Hum Hypertens"},{"key":"B80","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1311989","article-title":"Association of urinary sodium and potassium excretion with blood pressure","volume":"371","author":"Mente","year":"2014","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.jhh.1001459","article-title":"Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health","volume":"16","author":"He","year":"2002","journal-title":"J Hum Hypertens"},{"key":"B82","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/HYPERTENSIONAHA.111.00058","article-title":"Aerobic exercise reduces blood pressure in resistant hypertension","volume":"60","author":"Dimeo","year":"2012","journal-title":"Hypertension"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"B84","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.amjmed.2011.12.010","article-title":"Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients","volume":"125","author":"Ogawa","year":"2012","journal-title":"Am J Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/HYPERTENSIONAHA.111.190637","article-title":"Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate","volume":"59","author":"Peterzan","year":"2012","journal-title":"Hypertension"},{"key":"B87","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1161\/CIRCULATIONAHA.108.828897","article-title":"Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark?","volume":"119","author":"Messerli","year":"2009","journal-title":"Circulation"},{"key":"B88","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jacc.2010.07.053","article-title":"Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials","volume":"57","author":"Messerli","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/01.CIR.79.3.721","article-title":"Office evaluation of hypertension. A statement for health professionals by a writing group of the council for high blood pressure research, American Heart Association","volume":"79","author":"Gifford","year":"1989","journal-title":"Circulation"},{"key":"B90","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (The symplicity HTN-2 Trial): a randomised controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/hr.2014.139","article-title":"Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension","volume":"37","author":"Rossi","year":"2014","journal-title":"Hypertens Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/0002-9149(76)90409-4","article-title":"Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity","volume":"37","author":"Karlberg","year":"1976","journal-title":"Am J Cardiol"},{"key":"B96","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cpt1978245525","article-title":"Antihypertensive responses to spironolactone in normal renin hypertension","volume":"24","author":"Ogilvie","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"B97","first-page":"31","article-title":"Comparison of chlorthalidone and spironolactone in low \u00e2\u20ac\u201c renin essential hypertension","volume":"128","author":"Kreeft","year":"1983","journal-title":"Can Med Assoc J"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/hy1101.095010","article-title":"Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects","volume":"38","author":"Pratt","year":"2001","journal-title":"Hypertension"},{"key":"B99","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin Ther"},{"key":"B101","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney Int"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"key":"B105","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am J Cardiol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"B108","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"B109","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"key":"B111","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"B112","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","article-title":"Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension","volume":"19","author":"Sharabi","year":"2006","journal-title":"Am J Hypertens"},{"key":"B113","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","article-title":"Low-dose spironolactone in the management of resistant hypertension: a surveillance study","volume":"25","author":"Lane","year":"2007","journal-title":"J Hypertens"},{"key":"B114","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"key":"B115","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"B116","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension","volume":"31","author":"Colussi","year":"2013","journal-title":"J Hypertens"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1345\/aph.1P338","article-title":"Spironolactone management of resistant hypertension","volume":"44","author":"Marrs","year":"2010","journal-title":"Ann Pharmacother"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"Vaclavik","year":"2011","journal-title":"Hypertension"},{"key":"B120","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B121","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens"},{"key":"B122","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","article-title":"Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/hr.2014.77","article-title":"Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension","volume":"37","author":"Shlomai","year":"2014","journal-title":"Hypertens Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1177\/0091270003258189","article-title":"Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?","volume":"43","author":"Prisant","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/HJH.0b013e328332b79b","article-title":"Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO","volume":"28","author":"Parthasarathy","year":"2010","journal-title":"J Hypertens"},{"key":"B127","doi-asserted-by":"publisher","first-page":"783","DOI":"10.7326\/0003-4819-90-5-783","article-title":"Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism","volume":"90","author":"Tan","year":"1979","journal-title":"Ann Intern Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T17:29:24Z","timestamp":1598722164000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fcvm.2015.00003\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,4]]},"references-count":127,"URL":"https:\/\/doi.org\/10.3389\/fcvm.2015.00003","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,4]]}}}